Back to News & Events

SBIR/ATTR Awardees: Open Eligibility for Needs Assessment Report

Companies with an active NIH SBIR or STTR Phase I or Phase I Fast-Track award (grant or contract) within the past two years are eligible to receive a Technical and Business Assistance (TABA) Program Needs Assessment Report*

The TABA Needs Assessment Report provides a third party, unbiased assessment of your progress in 10 technical and business areas that are critical to success in the competitive healthcare marketplace including Target Market Attractiveness (Need/Size), Ability to Address Market Need, Regulatory Path and more. Learn more: https://sbir.nih.gov/support-for-awardees/taba-needs-assessment

*For companies with multiple awards, only one project will be considered for the program. Small businesses that have received TABA funding within their Phase I award are not eligible to participate.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3820 [post_author] => 4 [post_date] => 2021-09-20 15:59:29 [post_date_gmt] => 2021-09-20 15:59:29 [post_content] =>

NYSTAR and FuzeHub invite you to the New York State Innovation Summit on November 8-9, 2021 at the Turning Stone in Verona, NY. This multi-day event for NYS organizations that want to showcase and discover new and emerging technologies that support innovation and drive business growth. Whether you’re a startup, an economic developer, or an established manufacturer, the NYS Innovation Summit is for you.

The 2021 New York State Innovation Summit will showcase companies and researchers at the forefront of emerging technologies and new advancements in production capabilities. This event celebrates New York State leadership in technology-led economic growth with experts in biotechnology, new materials, energy innovation, and artificial intelligence that will explore current technology convergence opportunities, ways to accelerate commercialization, and issues of manufacturing sustainability.

This year’s Innovation Summit includes the New York State Commercialization Competition and speakers from top companies such as Cree, Plug Power, Velan Studios and Verizon 5G Labs.

For more information, or to register, visit nysinnovationsummit.com.

[post_title] => New York State Innovation Summit [post_excerpt] => NYSTAR and FuzeHub present the New York State Innovation Summit on November 8-9, 2021 at the Turning Stone in Verona, NY. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => new-york-state-innovation-summit [to_ping] => [pinged] => [post_modified] => 2022-08-22 13:09:12 [post_modified_gmt] => 2022-08-22 13:09:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3820 [menu_order] => 37 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3924 [post_author] => 4 [post_date] => 2022-09-12 15:44:45 [post_date_gmt] => 2022-09-12 15:44:45 [post_content] =>

The Center for Biotechnology recently co-hosted a startup series focused on providing guidance and insight into how innovators can take their solution from the benchtop to the Biomedical Advanced Research & Development Authority (BARDA).

Produced in collaboration with our fellow BARDA Division of Research, Innovation & Ventures (DRIVe) accelerators, each of the six sessions focused on key start up topics and were led by experts with providing an overview of key resources available to innovators to help fund and advance their solution from early through late stages of development, as well as provide guidance on how to navigate the funding opportunities within BARDA and BARDA DRIVe.

Look for our announcements of additional offerings from the BARDA DRIVe network soon, including the upcoming BARDA Industry Day on November 15-16, 2022.

[post_title] => Successful Launch: Bench to BARDA Startup Series [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => successful-launch-bench-to-barda-startup-series [to_ping] => [pinged] => [post_modified] => 2023-07-10 12:41:49 [post_modified_gmt] => 2023-07-10 16:41:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3924 [menu_order] => 21 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2913 [post_author] => 1 [post_date] => 2018-01-10 15:34:32 [post_date_gmt] => 2018-01-10 15:34:32 [post_content] => Celmatix, a next-generation women’s health company, has been awarded $4.5 million from Empire State Development’s New York City Regional Economic Development Council (REDC), to expand its headquarters in Manhattan. Piraye Yurttas Beim, PhD, Founder and CEO of Celmatix stated “New York State has been there for Celmatix every step of the way as we’ve transitioned from ambitious startup to innovative next generation women’s health company. From the training I received through New York State’s Center for Biotechnology program at Stony Brook University, to the support we received from the Empire State Development START-UP New York program when it was time to build our first lab, and now, with this award as we prepare to take the next step in the evolution of our company, we are honored to have continued support to grow and thrive in New York.” Additional Articles: pharmiweb [post_title] => Celmatix awarded $4.5M to expand in NYS [post_excerpt] => Celmatix receives $4.5 million to expand its headquarters in Manhattan. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => celmatix-awarded-4-5m-to-expand-in-nys [to_ping] => [pinged] => [post_modified] => 2018-02-02 19:23:34 [post_modified_gmt] => 2018-02-02 19:23:34 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2913 [menu_order] => 128 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 261 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

New York State Innovation Summit

More Information

Successful Launch: Bench to BARDA Startup Series

More Information

Celmatix awarded $4.5M to expand in NYS

More Information